Develops and licenses biotechnology intellectual property.
Dyadic International, Inc., headquartered in Jupiter, Florida, operates as a pioneering biotechnology platform company focused on the development, production, and commercialization of enzymes and other proteins within the United States. Central to its operations is the utilization of its patented and proprietary C1 platform alongside other cutting-edge technologies. These enable Dyadic to conduct extensive research, development, and commercial activities aimed at advancing human and animal vaccines, as well as various drugs. The company's diverse product portfolio includes virus-like particles, antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and therapeutic enzymes and proteins.
Dyadic International is actively advancing its vaccine development initiatives, with its DYAI-100 SARS-CoV-2-RBD antigen vaccine candidate progressing towards a pivotal Phase 1 clinical trial. This milestone aims to validate its potential as a proof of concept for the development of next-generation multivariant COVID-19 vaccine candidates. In addition to its internal research efforts, Dyadic has established strategic collaborations with key entities in the biotechnology sector. These include a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited.
Founded in 1979, Dyadic International continues to leverage its extensive experience and technological expertise to drive innovations in biotechnology. With a steadfast commitment to advancing medical and scientifgic progress, the company remains dedicated to addressing global healthcare challenges and improving patient outcomes through its transformative protein-based solutions.